Ascletis Doses First Participants in U.S. Phase I Trial of ASC50, an Oral IL-17 Inhibitor for Psoriasis

Ascletis Doses First Participants in U.S. Phase I Trial of ASC50, an Oral IL-17 Inhibitor for Psoriasis

By, Admin 18 June 2025

Overview

Ascletis Pharma Inc. (HKEX: 1672, ""Ascletis"") announces that the first healthy participants have been dosed in a randomized, double-blind, placebo-controlled Phase I clinical trial in the U.S., evaluating the safety, tolerability and preliminary efficacy of ASC50 (NCT07024602) for the treatment of psoriasis. ASC50 is an in-house discovered and developed oral small molecule inhibitor targeting interleukin-17 (IL-17), an important biologically and commercially validated target for multiple autoimmune and inflammatory diseases, including psoriasis.

Phase I clinical trial

  • The Phase I clinical trial of ASC50 oral tablets, conducted at multiple sites in the U.S., is a randomized, double-blind, placebo-controlled, first-in-human study of both healthy participants and patients with mild-to-moderate plaque psoriasis. 
  • ASC50 oral tablets are developed in house at Ascletis.

""We are pleased to announce completion of dosing of the first participants ahead of schedule and to begin clinical development of ASC50 for psoriasis."" said Jinzi Jason Wu, Ph.D., Founder, Chairman and CEO of Ascletis, ""We are looking forward to the topline data from this study in the near future.""

About Ascletis Pharma Inc.

  • Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the development and commercialization of potential best-in-class and first-in-class therapeutics to treat metabolic diseases. 
  • Utilizing its proprietary Artificial Intelligence-Assisted Structure-Based Drug Discovery (AISBDD) Platform and Ultra-Long-Acting Platform (ULAP), Ascletis has developed multiple drug candidates in-house, including its lead program, ASC30, a small molecule GLP-1R agonist in development as a once-daily oral tablet and once-monthly subcutaneous injection for weight management. Ascletis is listed on the Hong Kong Stock Exchange (1672.HK).

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!